Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Ophthalmology

Location and Behavior: How Subtypes Affect Your Care

At a Glance

Uveitis is classified into four subtypes based on where eye inflammation occurs: anterior (front), intermediate (middle), posterior (back), and panuveitis (entire eye). The location determines your symptoms, your risk for permanent vision loss, and whether you need eye drops or systemic medication.

The eye is a complex organ with several distinct compartments. To provide the best care, doctors use a global standard called the SUN criteria (Standardization of Uveitis Nomenclature) to classify exactly where the inflammation is occurring [1][2]. Understanding your specific subtype is essential, as the location of the inflammation determines your symptoms, the risk to your vision, and which systemic diseases your doctor might look for.

The Four Anatomical Subtypes

1. Anterior Uveitis (Front of the Eye)

This is the most common form of uveitis [3][4]. It affects the iris (the colored part of the eye) and the ciliary body (the structure right behind it).

  • Behavior: Often starts suddenly and is characterized by redness, pain, and light sensitivity [5].
  • Systemic Links: Frequently associated with the HLA-B27 genetic marker and conditions like Ankylosing Spondylitis (spinal inflammation) or inflammatory bowel disease [6][7].
  • Vision Risk: Generally lower risk for permanent vision loss if treated promptly with steroid eye drops [8].

2. Intermediate Uveitis (Middle of the Eye)

This type primarily affects the vitreous, the jelly-like substance that fills the center of the eye [9].

  • Behavior: Typically chronic (long-lasting) and painless. The main symptom is “floaters” or hazy vision [5].
  • Systemic Links: Can be associated with Multiple Sclerosis or Sarcoidosis, though it is often limited only to the eye [10][11].

3. Posterior Uveitis (Back of the Eye)

This involves the retina (the light-sensitive tissue) and the choroid (the layer of blood vessels behind the retina) [5].

  • Behavior: Often painless but causes significant blurring or dark spots in the vision.
  • Systemic Links: Can be caused by infections like Toxoplasmosis or Syphilis, or autoimmune conditions like Lupus [12][13].
  • Vision Risk: High. Because it occurs near the macula (responsible for sharp, central vision), it can lead to permanent scarring or fluid buildup [14][15].

4. Panuveitis (The Entire Eye)

In this subtype, inflammation is present in all parts of the eye—the front, middle, and back [5].

  • Behavior: Carries the highest risk for severe and permanent vision impairment because the entire eye is under attack [14][16].
  • Systemic Links: Strongest association with systemic diseases like Behçet’s Disease, Vogt-Koyanagi-Harada (VKH), and Sarcoidosis [17][18].
  • Vision Risk: Very High. Patients with panuveitis often require aggressive treatment with oral medications or biologics (targeted immune therapies) to save their sight [19][20].

Why Location Matters for Your Sight

The closer the inflammation is to the back of the eye, the more “sight-threatening” it becomes. While Anterior Uveitis can usually be managed with eye drops, Posterior and Panuveitis often require systemic treatments—pills, injections, or infusions—because drops cannot reach the back of the eye effectively [21][8].

Inflammation in the posterior segment can cause Cystoid Macular Edema (CME), which is fluid buildup in the center of the retina. This is the leading cause of vision loss in uveitis patients [22][23]. Knowing your subtype helps your care team stay one step ahead of these complications.

Common questions in this guide

What is the most common type of uveitis?
Anterior uveitis is the most common form of eye inflammation. It affects the front of the eye, specifically the iris and ciliary body, and typically causes sudden redness, pain, and light sensitivity.
Why does it matter where my uveitis is located?
The location of inflammation determines your risk for vision loss and what treatments will work. Inflammation in the front of the eye can often be treated with drops, while inflammation in the back usually requires pills, injections, or infusions because drops cannot reach it.
What causes intermediate and posterior uveitis?
These subtypes can occur on their own or be linked to other diseases. Intermediate uveitis is sometimes associated with multiple sclerosis or sarcoidosis, while posterior uveitis can be caused by infections or autoimmune conditions like lupus.
What does panuveitis mean?
Panuveitis occurs when inflammation affects all parts of the eye—the front, middle, and back. It carries the highest risk for severe vision impairment and often requires aggressive treatment with oral medications or biologic therapies to protect your sight.
How does posterior uveitis affect my vision?
Posterior uveitis affects the retina and choroid, which are near the macula. This inflammation can cause fluid buildup called cystoid macular edema (CME), which is the leading cause of permanent vision loss for uveitis patients.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How does the anatomical location of my uveitis change the type of treatment I need (e.g., drops vs. pills vs. injections)?
  2. 2.Given that I have posterior or panuveitis, what are we doing specifically to monitor and protect my macula and optic nerve?
  3. 3.Does my specific subtype suggest I should be screened for systemic conditions like sarcoidosis or ankylosing spondylitis?
  4. 4.Since my uveitis is located in the back of the eye, how often should I have an OCT (Optical Coherence Tomography) scan to check for fluid?
  5. 5.Is the inflammation in my eye considered 'granulomatous,' and how does that help you narrow down the cause?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    [Development of classification criteria for uveitis by the standardization of uveitis nomenclature (SUN) working group].

    Heiligenhaus A, Rothaus K, Pleyer U

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2021; (118(9)):913-918 doi:10.1007/s00347-021-01486-2.

    PMID: 34459962
  2. 2

    Pediatric uveitis: A comprehensive review.

    Maleki A, Anesi SD, Look-Why S, et al.

    Survey of ophthalmology 2022; (67(2)):510-529 doi:10.1016/j.survophthal.2021.06.006.

    PMID: 34181974
  3. 3

    Epidemiology of Uveitis from a Tertiary Referral Hospital in Bulgaria over a 13-Year Period.

    Mitkova-Hristova VT, Atanassov MA, Basheva-Kraeva YM, et al.

    Diagnostics (Basel, Switzerland) 2025; (15(7)) doi:10.3390/diagnostics15070828.

    PMID: 40218176
  4. 4

    Patterns of Uveitis among Patients Attending Jimma University Department of Ophthalmology, Jimma, Ethiopia.

    Tolesa K, Abateneh A, Kempen JH, Gelaw Y

    Ocular immunology and inflammation 2020; (28(7)):1109-1115 doi:10.1080/09273948.2019.1644348.

    PMID: 31429610
  5. 5

    Etiology and Anatomical Location of Uveitis-Prognostic Factors for Disease Course and Laterality.

    Mitkova-Hristova VT, Atanassov MA

    Life (Basel, Switzerland) 2025; (15(6)) doi:10.3390/life15060882.

    PMID: 40566536
  6. 6

    Ten-Year Registry Analysis of Ocular Inflammation in Taiwan: Distinct Clinical Patterns and Systemic Associations in Adults and Children.

    Sun WH, Wang LU, Wang JK, et al.

    Ocular immunology and inflammation 2026; (34(2)):325-333 doi:10.1080/09273948.2025.2607621.

    PMID: 41529241
  7. 7

    Classification Criteria for Spondyloarthritis/HLA-B27-Associated Anterior Uveitis.

    American journal of ophthalmology 2021; (228()):117-125 doi:10.1016/j.ajo.2021.03.049.

    PMID: 33845004
  8. 8

    Management of Acute Non-Infectious Anterior Uveitis in Adults - Practice Patterns Among Uveitis Specialists in North America.

    Zhang H, Nicholson CM, Kempen JH, et al.

    Ocular immunology and inflammation 2025; (33(7)):1153-1158 doi:10.1080/09273948.2024.2346819.

    PMID: 38749068
  9. 9

    Epidemiology of Intermediate Uveitis.

    Besagar S, de-la-Torre A, Thorne J, et al.

    Ocular immunology and inflammation 2025; (33(4)):503-511 doi:10.1080/09273948.2024.2408411.

    PMID: 39360991
  10. 10

    Pattern of Intermediate Uveitis in an Egyptian Cohort.

    Abd El Latif E, Abdelhalim AS, Montasser AS, et al.

    Ocular immunology and inflammation 2020; (28(3)):524-531 doi:10.1080/09273948.2019.1668429.

    PMID: 31642742
  11. 11

    Clinical Features of Japanese Patients with Ocular Inflammation and Their Surgical Procedures Over the Course of 20 Years.

    Takai N, Kobayashi T, Kida T, Ikeda T

    Clinical ophthalmology (Auckland, N.Z.) 2020; (14()):2799-2806 doi:10.2147/OPTH.S273938.

    PMID: 33061264
  12. 12

    Ocular Syphilis: The Resurgence of an Old Disease Experience of a Tertiary Centre in Portugal.

    Costa C, Machado T, Zhu A, et al.

    Ocular immunology and inflammation 2025; (33(3)):385-395 doi:10.1080/09273948.2024.2413902.

    PMID: 39388630
  13. 13

    Clinical Profile and Visual Outcomes of Ocular Syphilis: A Five-year Review in Hospital Universiti Sains, Malaysia.

    Ghanimi Zamli AK, Irma Ngah NS, Chew-Ean T, et al.

    Cureus 2019; (11(2)):e4015 doi:10.7759/cureus.4015.

    PMID: 31007973
  14. 14

    Prevalence, Treatment Patterns, and Outcomes of Pediatric Noninfectious Uveitis in the United States: An IRIS Registry Analysis.

    Uner OE, Lin P, Kopplin LJ, et al.

    Ophthalmology. Retina 2025; (9(11)):1106-1113 doi:10.1016/j.oret.2025.05.006.

    PMID: 40349981
  15. 15

    Prevalence, clinical characteristics, and independent predictors of uveitic macular edema in an Asian population: a retrospective cohort study.

    Tungsattayathitthan U, Jenjanya S, Choopong P, et al.

    BMC ophthalmology 2024; (24(1)):181 doi:10.1186/s12886-024-03447-0.

    PMID: 38649909
  16. 16

    [Prognostic factors in uveitis].

    Albaroudi N, Tijani M, Boutimzine N, et al.

    Journal francais d'ophtalmologie 2017; (40(9)):751-757 doi:10.1016/j.jfo.2017.04.005.

    PMID: 28882393
  17. 17

    The epidemiology of uveitis: comparison of its causes and visual outcomes between three-tiered medical facilities in Ube city.

    Yanai R, Uchi SH, Kondo Y, et al.

    Scientific reports 2025; (15(1)):8998 doi:10.1038/s41598-025-93223-x.

    PMID: 40089526
  18. 18

    Demographic Features, Diagnoses and Real-World Clinical Management of Uveitis in Japan.

    Hayashi I, Keino H, Nakayama M, et al.

    Ocular immunology and inflammation 2025; (33(7)):1077-1085 doi:10.1080/09273948.2024.2449179.

    PMID: 39792467
  19. 19

    [Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel].

    Diwo E, Sève P, Trad S, et al.

    La Revue de medecine interne 2018; (39(9)):687-698 doi:10.1016/j.revmed.2018.03.001.

    PMID: 29610003
  20. 20

    Efficacy and Safety of Adalimumab in Pediatric Non-infectious Non-anterior Uveitis: Real-life Experience From the International AIDA Network Uveitis Registry.

    Vitale A, Casa FD, Guerriero S, et al.

    Ophthalmology and therapy 2023; (12(4)):1957-1971 doi:10.1007/s40123-023-00712-1.

    PMID: 37166627
  21. 21

    Incidence and Predictors of Ocular Complications in Pediatric-Onset Uveitis: Data from the AIDA Network Uveitis Registry.

    Gaggiano C, De-la-Torre A, Cardona-López J, et al.

    Ophthalmology and therapy 2025; (14(11)):2877-2894 doi:10.1007/s40123-025-01237-5.

    PMID: 40983853
  22. 22

    Relationship of Epiretinal Membrane Formation and Macular Edema Development in a Large Cohort of Uveitic Eyes.

    Mustafi D, Do BK, Rodger DC, Rao NA

    Ocular immunology and inflammation 2021; (29(5)):915-921 doi:10.1080/09273948.2019.1704026.

    PMID: 31961201
  23. 23

    Pediatric Pars Planitis: A Review.

    Khochtali S, Ozdal P, AlBloushi AF, et al.

    Ocular immunology and inflammation 2023; (31(10)):1915-1929 doi:10.1080/09273948.2023.2279683.

    PMID: 37976519

This page explains uveitis subtypes and their symptoms for educational purposes only. Always consult an ophthalmologist to diagnose your specific type of eye inflammation and determine the most appropriate treatment plan.

Get notified when new evidence is published on Uveitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.